NEUROCRINE BIOSCIENCES
(NASDAQ: NBIX)

Neurocrine Biosciences, Inc. (Neurocrine) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company�s product candidates address some of the pharmaceutical markets including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine has 11 programs in various stages of research and development, including six programs in clinical development. It has entered into collaborations for six of its programs. Its lead clinical development program, elagolix, is a drug candidate for the treatment of endometriosis. The Company�s product portfolio include Elagolix, Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), CRF2 Peptide Agonist-urocortin 2, CRF1 Antagonist (561679), CRF1 Antagonist (586529), G Protein-Coupled Receptor 119 (GPR119), VMAT2, GnRH Antagonists, Antiepileptic Drugs, G Protein-Coupled Receptors and Indiplon.

135.420 s

+0.460 (+0.34%)
Range 134.120 - 137.010   (2.15%)
Open 134.980
Previous Close 134.960
Bid Price 93.640
Bid Volume 8
Ask Price 95.420
Ask Volume 8
Volume 1,924,000
Value -
Remark s
Delayed prices. Updated at 21 Dec 2024 05:00.
Data powered by
View All Events

About NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences, Inc. (Neurocrine) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. The Company�s product candidates address some of the pharmaceutical markets including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine has 11 programs in various stages of research and development, including six programs in clinical development. It has entered into collaborations for six of its programs. Its lead clinical development program, elagolix, is a drug candidate for the treatment of endometriosis. The Company�s product portfolio include Elagolix, Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), CRF2 Peptide Agonist-urocortin 2, CRF1 Antagonist (561679), CRF1 Antagonist (586529), G Protein-Coupled Receptor 119 (GPR119), VMAT2, GnRH Antagonists, Antiepileptic Drugs, G Protein-Coupled Receptors and Indiplon.

Loading Chart...

Please login to view stock data and analysis